Amgen's Q2 2018 earnings call highlighted strong financial performance, driven by robust sales of newer products like Aimovig and Repatha, and double-digit growth in non-US markets. Management emphasized the company's commitment to volume-driven growth and strategic investments in its pipeline.  The revised guidance, reflecting confidence in continued strong performance, suggests a positive short-term outlook for Amgen stock.
[1]
